Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that act by blocking checkpoint proteins on the surface of immune cells (such as cytotoxic T-lymphocyte antigen-4, CTLA-4, or programmed death-1, PD-1) from binding with their partner proteins on the tumor cells. This evidence concerns the gene CTLA4 and neoplasm.